Rina-S With or Without Bevacizumab for Ovarian Cancer

(RAINFOL™-07 Trial)

This trial tests the effectiveness of a new treatment, Rina-S, for ovarian cancer. Participants will receive either Rina-S alone, Rina-S with bevacizumab (a targeted therapy), or standard chemotherapy options with or without bevacizumab. The goal is to determine which treatment combination is most effective. Individuals with high-grade serous or endometrioid ovarian cancer that has recurred after initial platinum-based chemotherapy may qualify. Participants will regularly visit the study clinic for monitoring and can continue treatment as long as it remains beneficial. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Previous studies have shown that Rina-S is generally well-tolerated. Research indicates it is safe for use on its own, with patients not experiencing serious eye or lung problems, which are common concerns. Rina-S had manageable side effects, and no unexpected side effects appeared.

Bevacizumab, used with other treatments, has already received FDA approval for various cancers, indicating it is reasonably safe. However, it can sometimes cause high blood pressure or affect the kidneys.

Researchers are excited about Rina-S for ovarian cancer because it potentially offers a novel approach by either being used alone or in combination with bevacizumab, a well-known drug that targets blood vessels feeding tumors. Unlike traditional treatments like carboplatin paired with other chemotherapy agents, Rina-S could provide a unique mechanism targeting cancer cells differently. This new approach may enhance effectiveness or reduce side effects compared to existing chemotherapy options.

Research has shown that Rina-S may effectively treat ovarian cancer. One study found that up to 50% of patients experienced significant tumor shrinkage. Additionally, about 86.4% of patients maintained stable disease, with no progression. Some patients even achieved complete responses, where the cancer appeared to disappear entirely. In this trial, participants in one arm will receive Rina-S with or without Bevacizumab. These early results suggest that Rina-S could be a strong option for managing ovarian cancer, especially when other treatments have failed.²³⁴⁶⁷